Xenetic Biosciences
XBIO
8 hedge funds and large institutions have $443K invested in Xenetic Biosciences in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 6 → 8 (+2)
0.74% less ownership
Funds ownership: 7.38% → 6.64% (-0.74%)
2% less capital invested
Capital invested by funds: $453K → $443K (-$10.3K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$18.4K |
| 2 |
SS
SBI Securities
Tokyo,
Japan
|
+$3.09K |
| 3 |
Morgan Stanley
New York
|
+$463 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$61.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$12.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$340 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $342K | -$61.8K | -20,000 | -15% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $50.7K | -$12.4K | -4,018 | -19% |
|
|
3
Vanguard Capital Management
Malvern,
Pennsylvania
| $36.9K | +$18.4K | +5,950 | +88% |
|
|
JEST
4
JTC Employer Solutions Trustee
St Helier,
Jersey
| $8K | – | – | – |
|
|
SS
5
SBI Securities
Tokyo,
Japan
| $2.91K | +$3.09K | +1,000 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $2.02K | -$340 | -110 | -14% |
|
|
7
Morgan Stanley
New York
| $437 | +$463 | +150 | New |
|
|
DWM
8
Darwin Wealth Management
Tampa,
Florida
| $5 | – | – | – |
|
XBIO Hedge Fund Activity: Q2 2026 in Review
8 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q2 2026, worth a combined $443K — down 2.3% from $453K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new XBIO positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Capital Management, adding an estimated $18.4K. The largest seller was Renaissance Technologies, cutting an estimated $61.8K.
- 8 institutional investors held Xenetic Biosciences (XBIO) as of Q2 2026, up from 6 in Q1 2026.
- Funds reported $443K of Xenetic Biosciences stock for Q2 2026, down 2.3% quarter-over-quarter.
- 2 funds opened new Xenetic Biosciences positions in Q2 2026 and 0 closed out, a net change of +2 holders.
- The largest Xenetic Biosciences buyer in Q2 2026 was Vanguard Capital Management, an estimated $18.4K added.
- The largest Xenetic Biosciences seller in Q2 2026 was Renaissance Technologies, an estimated $61.8K sold.
Based on aggregated 13F filings for Q2 2026.